Inclusion Criteria:

-Advanced solid tumor
-Measurable disease, per RECIST v1.1
-Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-Adequate organ function

Exclusion Criteria:
-Has not recovered [recovery is defined as NCI CTCAE, version 5.0, grade ≤1] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements
-Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-3-600
-Progressive or symptomatic brain metastases
-Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection
-History of significant cardiac disease
-History of myelodysplastic syndrome (MDS) or AML
-History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded
-If female, is pregnant or breastfeeding

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 4/11/2024. Questions regarding updates should be directed to the study team contact.